280 related articles for article (PubMed ID: 37672049)
1. Current and novel infusion therapies for patients with Parkinson's disease.
Antonini A; D'Onofrio V; Guerra A
J Neural Transm (Vienna); 2023 Nov; 130(11):1349-1358. PubMed ID: 37672049
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Soileau MJ; Aldred J; Budur K; Fisseha N; Fung VS; Jeong A; Kimber TE; Klos K; Litvan I; O'Neill D; Robieson WZ; Spindler MA; Standaert DG; Talapala S; Vaou EO; Zheng H; Facheris MF; Hauser RA
Lancet Neurol; 2022 Dec; 21(12):1099-1109. PubMed ID: 36402160
[TBL] [Abstract][Full Text] [Related]
3. Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.
Rosebraugh M; Liu W; Neenan M; Facheris MF
J Parkinsons Dis; 2021; 11(4):1695-1702. PubMed ID: 34366380
[TBL] [Abstract][Full Text] [Related]
4. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.
Rosebraugh M; Stodtmann S; Liu W; Facheris MF
Parkinsonism Relat Disord; 2022 Apr; 97():68-72. PubMed ID: 35339102
[TBL] [Abstract][Full Text] [Related]
5. Novel Levodopa Formulations for Parkinson's Disease.
Freitas ME; Ruiz-Lopez M; Fox SH
CNS Drugs; 2016 Nov; 30(11):1079-1095. PubMed ID: 27743318
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-Carbidopa-Entacapone Intestinal Gel in Advanced Parkinson Disease: A Multicenter Real-Life Experience.
Szász JA; Dulamea AO; Constantin VA; Mureşanu DF; Dumbravă LP; Tiu C; Jianu DC; Simu M; Ene A; Axelerad A; Falup-Pecurariu C; Lungu M; Danci AG; Sabau M; Strilciuc Ş; Popescu BO
Am J Ther; 2024 May-Jun 01; 31(3):e209-e218. PubMed ID: 38460175
[TBL] [Abstract][Full Text] [Related]
7. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
9. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Giladi N; Gurevich T; Djaldetti R; Adar L; Case R; Leibman-Barak S; Sasson N; Caraco Y
Parkinsonism Relat Disord; 2021 Oct; 91():139-145. PubMed ID: 34619438
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Silver DE
Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
[TBL] [Abstract][Full Text] [Related]
11. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
[TBL] [Abstract][Full Text] [Related]
12. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
13. Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson's disease: is it an improvement on other delivery?
Doggrell SA
Expert Opin Drug Deliv; 2023; 20(9):1189-1199. PubMed ID: 37634938
[TBL] [Abstract][Full Text] [Related]
14. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
15. Medical and surgical management of advanced Parkinson's disease.
Antonini A; Moro E; Godeiro C; Reichmann H
Mov Disord; 2018 Jul; 33(6):900-908. PubMed ID: 29570862
[TBL] [Abstract][Full Text] [Related]
16. Optimization of oral entacapone administration in patients undergoing levodopa-carbidopa intestinal gel treatment.
Miyaue N; Ito Y; Yamanishi Y; Tada S; Ando R; Yabe H; Nagai M
J Neurol Sci; 2024 Feb; 457():122901. PubMed ID: 38280299
[TBL] [Abstract][Full Text] [Related]
17. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile of levodopa-carbidopa-entacapone intestinal gel infusion in patients with advanced Parkinson's disease.
Atanasova-Ivanova KA; Hristova-Chakmakova SI; Milanov IG
Folia Med (Plovdiv); 2023 Dec; 65(6):929-932. PubMed ID: 38351782
[TBL] [Abstract][Full Text] [Related]
19. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
20. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
